Insights

article

The pre-filled syringe (PFS) space is one of the fastest growing pharma sectors, expected to be worth $9.7bn by 2025, or 9% CAGR. Compared with traditional vial delivery systems, PFS offers greater patient safety and lower manufacturing costs – bu...

article

As the COVID-19 outbreak continues to spread across the globe, Curia is diligently monitoring the latest developments.  As such, Curia has established a companywide taskforce to assure a coordinated response across our global network, focusing on em...

article

Syringes have been a mainstay of drug delivery for decades – but, as with many other aspects of healthcare, they have recently undergone something of a revolution. The growth of biological medications, the ever-increasing focus on safety, and a...

webinar

In this free webinar, the featured speaker will explore the key advances and critical hurdles for translating these emerging molecular biology technologies into real-world applications and commercial processes. Topics for discussion will include: a b...

article

Xtalks spoke with Dr. Steef Boerrigter, a senior research scientist at Curia and an expert at materials science. He has extensive experience with experimental screening technologies for polymorphs, salts and cocrystals and has developed computationa...

webinar

Curia offers more than 240 high-quality, competitively priced APIs and intermediates, including generics, that cover a variety of therapeutic areas. Take a look at our recently filed DMFs.

webinar

Oftentimes, the HPAPI sphere places the spotlight on manufacturing due to the containment challenges on large scale however; handling and containment strategies are also relevant in manufacture support roles such as chemical development, analytical...

webinar

The objective of this webinar is to address United States Pharmacopeia (USP) and FDA regulatory trends to demonstrate how to integrate various analytical tests into a robust program that addresses product integrity/compatibility throughout the produc...

webinar

Drug formulators should consider the physical properties of their products during pharmaceutical drug development. The physical properties of a solid drug substance are highly dependent on the solid form. It is critical to understand the solid form l...

article

Parenteral formulations are broadly characterized as sterile solutions, suspensions, emulsions, and powders for reconstitution for injection or infusion; they are administered directly to subjects, entering the systemic circulation and typically prov...

fact sheet

If you’re involved in late drug discovery, API manufacture, drug product formulation, clinical material production, or manufacture of final dosage form, a basic understanding and awareness of solid form issues could save you a great deal of difficu...

fact sheet

The term amorphous is used loosely in the pharmaceutical industry. A strict definition would limit amorphous to those materials which truly have no long range order, only the short range order characteristic of liquids. However, the term is popular...